Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | ME2 | P23368 | 1/20 | 0.42 |
| ▸ | ME1 | P48163 | 1/20 | 0.42 |
| ▸ | ME3 | Q16798 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875781 | 1.00 | NOTUM (0.47) | NOTUMSLC6A7DRD4DRD2HPGD | |
| SCHEMBL2873293 | 1.00 | NOTUM (0.47) | NOTUMSLC6A7DRD4DRD2HPGD | |
| SCHEMBL12193587 | 0.81 | SLC6A7 (0.51) | SLC6A7CHRM4CXCR3 | |
| SCHEMBL2470547 | 0.81 | SLC6A7 (0.51) | SLC6A7CHRM4CXCR3 | |
| SCHEMBL2875349 | 0.80 | CCR1 (0.62) | CHRM4CCR1 | |
| SCHEMBL2875351 | 0.80 | CCR1 (0.62) | CHRM4CCR1 | |
| SCHEMBL3464912 | 0.79 | CCR1 (0.51) | SMN1; SMN2CCR1 | |
| SCHEMBL3464913 | 0.79 | CCR1 (0.51) | SMN1; SMN2CCR1 | |
| SCHEMBL20047928 | 0.78 | SLC6A7 (0.41) | SLC6A7CHRM4CCR1CXCR3 | |
| SCHEMBL13184086 | 0.77 | CCR1 (0.50) | CHRM4CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7449576-B1 | potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone | CHEMOCENTRYX, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1531822-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | Chemocentryx, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | NOTUM 4652/4885SLC6A7 1112/4885DRD4 3277/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NOTUM 4652/4885SLC6A7 1112/4885DRD4 3277/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NOTUM 4580/4885SLC6A7 1374/4885DRD4 2666/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NOTUM 4580/4885SLC6A7 1374/4885DRD4 2666/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NOTUM 4652/4885SLC6A7 1112/4885DRD4 3277/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | NOTUM 4580/4885SLC6A7 1374/4885DRD4 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.